Stay updated on Lenvatinib and Pembrolizumab in HCC Clinical Trial
Sign up to get notified when there's something new on the Lenvatinib and Pembrolizumab in HCC Clinical Trial page.

Latest updates to the Lenvatinib and Pembrolizumab in HCC Clinical Trial page
- Check6 days agoChange DetectedA site-wide NIH notice announces updates and FAQs about the transition from “Artificial Intelligence” to “Super Intelligence” terminology.SummaryDifference1%

- Check13 days agoChange DetectedThe page remains a 403 Forbidden error. The footer revision identifier changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check20 days agoChange DetectedThe footer’s ClinicalTrials.gov revision identifier changes from v3.7.0 to v3.7.1 while the page continues to display a 403 error.SummaryDifference0.2%

- Check40 days agoChange DetectedThe page now shows a 403 Forbidden error, replacing the study record with a minimal error screen and navigation header.SummaryDifference18%

- Check61 days agoChange DetectedAn NIH funding note '2018 ( U.S. NIH Grant/Contract )' was added and a new page revision tag 'Revision: v3.6.6' was introduced, while the 'Plain Language Summary' and the previous revision tag 'Revision: v3.6.5' were removed.SummaryDifference0.1%

- Check82 days agoChange DetectedThe page now shows Revision: v3.6.5, replacing the previous Revision: v3.6.4, indicating a new build of the site.SummaryDifference0.0%

Stay in the know with updates to Lenvatinib and Pembrolizumab in HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenvatinib and Pembrolizumab in HCC Clinical Trial page.